Targeted Swedish HFE (haemochromatosis) screening is a possibility
This article was originally published in Clinica
Executive Summary
Screening for hereditary haemochromatosis could be introduced for a pre-defined target group, but it would be unwise to introduce general screening for the disease, says a new report from the Swedish council on technology assessment in healthcare (SBU). SBU believes that, although genetic screening would help to identify patients most at risk, it is uncertain as to how many of these would actually contract the disease and therefore require clinical treatment.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.